Special Issue "Genetics and Precision Medicine of Hepatobiliary Cancers and Pancreatic Cancers"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (31 December 2021).

Special Issue Editor

Dr. Hiroyuki Marusawa
E-Mail Website
Guest Editor
Department of Gastroenterology, Red-cross Osaka Hospital, Fudegasakicho 5-30, Tennojiku, Osaka, Japan
Interests: cancer genome; hepatocellular carcinoma; pancreatic cancer; inflammation

Special Issue Information

Dear Colleagues,

Recent innovations in next-generation sequencing (NGS) technologies are undergoing a paradigm shift in cancer diagnosis and treatment strategy. The NGS-based comprehensive genomic profiling assay is approved as a broad companion diagnostic that is clinically and analytically validated for various solid tumors. On the other hand, liquid biopsy is a minimally invasive procedure and can decrease the demand for tumor tissue samples. Recent progress of NGS-based assays has increased the sensitivity and specificity for detection of the mutant alleles in the liquid biopsy method, which supports the potential of liquid biopsy for diagnosis, early detection, selection of therapy, and monitoring the response to therapy. Therefore, the combination of medicinal innovation and NGS-based assays would mark a new era of precision cancer medicine.

In this Special Issue, we will focus on the genetics and precision medicine of cancers developed in the liver, bile duct and pancreas, and welcome submissions of original research and review manuscripts that cover basic and/or clinical aspects of hepatocellular carcinoma, biliary and pancreatic cancers.

Dr. Hiroyuki Marusawa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver cancer
  • bile duct cancer
  • pancreatic cancer
  • genetics
  • precision medicine
  • next-generation sequencing
  • liquid biopsy
  • early detection
  • therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Genetic Landscape of Multistep Hepatocarcinogenesis
Cancers 2022, 14(3), 568; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14030568 - 23 Jan 2022
Viewed by 181
Abstract
Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Although several targeted therapy agents are available for advanced HCC, their antitumor efficacy remains limited. As the complex genetic landscape of HCC would compromise the antitumor efficacy of targeted therapy, a deeper [...] Read more.
Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Although several targeted therapy agents are available for advanced HCC, their antitumor efficacy remains limited. As the complex genetic landscape of HCC would compromise the antitumor efficacy of targeted therapy, a deeper understanding of the genetic landscape of hepatocarcinogenesis is necessary. Recent comprehensive genetic analyses have revealed the driver genes of HCC, which accumulate during the multistage process of hepatocarcinogenesis, facilitating HCC genetic heterogeneity. In addition, as early genetic changes may represent key therapeutic targets, the genetic landscapes of early HCC and precancerous liver tissues have been characterized in recent years, in parallel with the advancement of next-generation sequencing analysis. In this review article, we first summarize the landscape of the liver cancer genome and its intratumor heterogeneity. We then introduce recent insight on early genetic alterations in hepatocarcinogenesis, especially those in early HCC and noncancerous liver tissues. Finally, we summarize the multistep accumulation of genetic aberrations throughout cancer progression and discuss the future perspective towards the clinical application of this genetic information. Full article
Back to TopTop